Cannabis for Rheumatic Disease Pain: Growing Interest, Limited Clinical Evidence | Research

The takeaway

While interest in cannabis for rheumatic disease pain has surged and patients report benefits, the clinical literature remains heavily weighted toward reviews rather than original research, with very few randomized trials.

Rheumatologists; patients with chronic inflammatory joint conditions; researchers planning clinical trials in rheumatic disease.

Literature skews heavily toward reviews vs. primary research

What the researchers found

Publications on cannabis and rheumatic disease have increased, but recent literature skews heavily toward reviews over primary research. Survey studies show patients find cannabis beneficial, but prospective controlled trials remain rare.

Why it matters

Rheumatic diseases cause chronic pain that is often difficult to manage. Patients are increasingly using cannabis on their own, so rheumatologists need to understand the current evidence (or lack thereof) to guide conversations with patients.

The numbers in context

The review noted that the number of publications has increased but skews toward reviews rather than original research. Specific survey data showed increased cannabis use among people with rheumatic diseases.

How the study worked

Narrative review of current literature on cannabis for rheumatic disease pain, covering observational studies, surveys, and the limited randomized controlled trial data available through 2022.

What this study cannot tell us

This is a narrative review, not a systematic review with formal quality assessment. The conclusions are shaped by the absence of evidence (few RCTs exist) rather than evidence of absence.

How to read the evidence

Moderate: comprehensive narrative review from rheumatology experts, though limited by the scarcity of underlying RCT evidence.

When this study was published

Published in 2022.

The bigger picture

This reflects a broader pattern in cannabis medicine: patient adoption has outpaced clinical evidence. The growing gap between what patients believe and what rigorous research has confirmed creates challenges for clinicians.

Questions still open

When will adequately powered RCTs on cannabis for rheumatic pain be completed? Which cannabinoid formulations and delivery methods are most promising for rheumatic conditions? How should rheumatologists counsel patients who are already using cannabis?

Common questions

Does cannabis work for arthritis pain?

Patient surveys suggest many find it helpful, and preclinical data supports potential anti-inflammatory and analgesic effects. However, rigorous human trials are largely missing, so the clinical evidence remains weak.

What should rheumatology patients know about cannabis?

The review suggests that while the data is growing, it is not yet strong enough to make firm recommendations. Patients interested in cannabis should discuss it with their rheumatologist rather than self-treating.

Read the original research

Cannabis for Rheumatic Disease Pain: a Review of Current Literature.

Current rheumatology reports, 24(5), 119-131

View on PubMed ↗Publisher’s paper ↗

Citation

Nowell, William Benjamin; Gavigan, Kelly; L Silverman, Stuart. (2022). Cannabis for Rheumatic Disease Pain: a Review of Current Literature.. Current rheumatology reports, 24(5), 119-131. https://doi.org/10.1007/s11926-022-01065-7